The Generation and Preclinical Evaluation of Homodimeric Anti-Her-2 Antibodies
Final rept. 1 Oct 1998-31 Mar 2001
TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
Pagination or Media Count:
Her-2neu has been selected as a target for immunotherapy based on its prevalence on a variety of tumor cells and the poor prognosis associated with its overexpression. From a panel of a hundred alpha-Her-2 MAbs we have characterized eleven with the highest affinity for Her-2 for further study in the treatment of prostate cancer. Three were eventually chosen for testing as homodimers and all induced substantially more growth arrest and death in vitro than their corresponding monomers. Work has also begun converting a number of these MAbs into mousehuman chimeric IgG1kappa into which we have incorporated cysteine residues for homodimer formation. These genetic dimers will be evaluated for efficacy in our in vitro models.
- Medicine and Medical Research